Therefore, we proposed that PTPN2 gene therapy may reduce the expression of pro‐inflammatory and pro‐fibrotic cytokines via inhibiting STAT1/3 signalling pathway and thus improve renal lesions and fibrosis in DN. The gene discussed is PTPN2; the disease is liver dysplastic nodule.